In Brief: Influence, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Influence, Inc.: Firm's Influ-ENT division launches the Repose surgical system for treatment of obstructive sleep apnea and snoring. The minimally invasive chin bone screw system is intended for use in stabilizing the tongue and preventing it from "collapsing back and obstructing the airway passage," Influence states in a Feb. 3 release. Formerly named the Sleep-In, the device was cleared via 510(k) Aug. 25. The launch was delayed until three-month post-treatment sleep study data could be accumulated and compared to pre-treatment data, Influence explains...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.